Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia : A single-center cohort study
© 2020 Wiley Periodicals LLC..
Coronavirus disease 2019 (COVID-19) can lead to a massive cytokine release. The use of the anti-interleukin-6 receptor monoclonal antibody tocilizumab (TCZ) has been proposed in this hyperinflammatory phase, although supporting evidence is limited. We retrospectively analyzed 88 consecutive patients with COVID-19 pneumonia that received at least one dose of intravenous TCZ in our institution between 16 and 27 March 2020. Clinical status from day 0 (first TCZ dose) through day 14 was assessed by a 6-point ordinal scale. The primary outcome was clinical improvement (hospital discharge and/or a decrease of ≥2 points on the 6-point scale) by day 7. Secondary outcomes included clinical improvement by day 14 and dynamics of vital signs and laboratory values. Rates of clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88). Previous or concomitant receipt of subcutaneous interferon-β (adjusted odds ratio [aOR]: 0.23; 95% confidence interval [CI]: 0.06-0.94; P = .041) and serum lactate dehydrogenase more than 450 U/L at day 0 (aOR: 0.25; 95% CI: 0.06-0.99; P = .048) were negatively associated with clinical improvement by day 7. All-cause mortality was 6.8% (6/88). Body temperature and respiratory and cardiac rates significantly decreased by day 1 compared to day 0. Lymphocyte count and pulse oximetry oxygen saturation/FiO2 ratio increased by days 3 and 5, whereas C-reactive protein levels dropped by day 2. There were no TCZ-attributable adverse events. In this observational single-center study, TCZ appeared to be useful and safe as immunomodulatory therapy for severe COVID-19 pneumonia.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
---|---|
Enthalten in: |
Journal of medical virology - 93(2021), 2 vom: 30. Feb., Seite 831-842 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Fernández-Ruiz, Mario [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.01.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/jmv.26308 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM312492774 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM312492774 | ||
003 | DE-627 | ||
005 | 20231225144529.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jmv.26308 |2 doi | |
028 | 5 | 2 | |a pubmed24n1041.xml |
035 | |a (DE-627)NLM312492774 | ||
035 | |a (NLM)32672860 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Fernández-Ruiz, Mario |e verfasserin |4 aut | |
245 | 1 | 0 | |a Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia |b A single-center cohort study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.01.2021 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 Wiley Periodicals LLC. | ||
520 | |a Coronavirus disease 2019 (COVID-19) can lead to a massive cytokine release. The use of the anti-interleukin-6 receptor monoclonal antibody tocilizumab (TCZ) has been proposed in this hyperinflammatory phase, although supporting evidence is limited. We retrospectively analyzed 88 consecutive patients with COVID-19 pneumonia that received at least one dose of intravenous TCZ in our institution between 16 and 27 March 2020. Clinical status from day 0 (first TCZ dose) through day 14 was assessed by a 6-point ordinal scale. The primary outcome was clinical improvement (hospital discharge and/or a decrease of ≥2 points on the 6-point scale) by day 7. Secondary outcomes included clinical improvement by day 14 and dynamics of vital signs and laboratory values. Rates of clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88). Previous or concomitant receipt of subcutaneous interferon-β (adjusted odds ratio [aOR]: 0.23; 95% confidence interval [CI]: 0.06-0.94; P = .041) and serum lactate dehydrogenase more than 450 U/L at day 0 (aOR: 0.25; 95% CI: 0.06-0.99; P = .048) were negatively associated with clinical improvement by day 7. All-cause mortality was 6.8% (6/88). Body temperature and respiratory and cardiac rates significantly decreased by day 1 compared to day 0. Lymphocyte count and pulse oximetry oxygen saturation/FiO2 ratio increased by days 3 and 5, whereas C-reactive protein levels dropped by day 2. There were no TCZ-attributable adverse events. In this observational single-center study, TCZ appeared to be useful and safe as immunomodulatory therapy for severe COVID-19 pneumonia | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a immunomodulation | |
650 | 4 | |a pneumonia | |
650 | 4 | |a tocilizumab | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Immunologic Factors |2 NLM | |
650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
650 | 7 | |a Interferon-beta |2 NLM | |
650 | 7 | |a 77238-31-4 |2 NLM | |
650 | 7 | |a C-Reactive Protein |2 NLM | |
650 | 7 | |a 9007-41-4 |2 NLM | |
650 | 7 | |a L-Lactate Dehydrogenase |2 NLM | |
650 | 7 | |a EC 1.1.1.27 |2 NLM | |
650 | 7 | |a tocilizumab |2 NLM | |
650 | 7 | |a I031V2H011 |2 NLM | |
700 | 1 | |a López-Medrano, Francisco |e verfasserin |4 aut | |
700 | 1 | |a Pérez-Jacoiste Asín, María Asunción |e verfasserin |4 aut | |
700 | 1 | |a Maestro de la Calle, Guillermo |e verfasserin |4 aut | |
700 | 1 | |a Bueno, Héctor |e verfasserin |4 aut | |
700 | 1 | |a Caro-Teller, José Manuel |e verfasserin |4 aut | |
700 | 1 | |a Catalán, Mercedes |e verfasserin |4 aut | |
700 | 1 | |a de la Calle, Cristina |e verfasserin |4 aut | |
700 | 1 | |a García-García, Rocío |e verfasserin |4 aut | |
700 | 1 | |a Gómez, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Laguna-Goya, Rocío |e verfasserin |4 aut | |
700 | 1 | |a Lizasoáin, Manuel |e verfasserin |4 aut | |
700 | 1 | |a Martínez-López, Joaquín |e verfasserin |4 aut | |
700 | 1 | |a Origüen, Julia |e verfasserin |4 aut | |
700 | 1 | |a Pablos, José Luis |e verfasserin |4 aut | |
700 | 1 | |a Ripoll, Mar |e verfasserin |4 aut | |
700 | 1 | |a San Juan, Rafael |e verfasserin |4 aut | |
700 | 1 | |a Trujillo, Hernando |e verfasserin |4 aut | |
700 | 1 | |a Lumbreras, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Aguado, José María |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 93(2021), 2 vom: 30. Feb., Seite 831-842 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
773 | 1 | 8 | |g volume:93 |g year:2021 |g number:2 |g day:30 |g month:02 |g pages:831-842 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.26308 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 93 |j 2021 |e 2 |b 30 |c 02 |h 831-842 |